文献速递心力衰竭与心肌病

Ⅲ期多发性骨髓瘤试验中的心血管疾病与淀粉样变性:系统综述

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting
RSS 订阅 · Open Heart

研究评估了试验对淀粉样变性和心血管疾病的入排标准、筛查及事件报告情况。结果显示98%的试验含心血管排除标准,但仅1项报告基线心血管特征,心脏淀粉样变性筛查缺失,心血管不良事件报告欠佳。

要点

  • 淀粉样变性在30项试验中为排除标准,但均未主动筛查心脏淀粉样变性
  • 98%的试验至少含一项心血管排除标准,最常见为心衰和近期心梗
  • 心血管不良事件为研究者报告,定义不一致且无中心化裁定

核心结论

  • Ⅲ期多发性骨髓瘤试验常设淀粉样变性和心血管疾病排除标准,但心脏淀粉样变性及心血管疾病患病率仍不明确
  • 心血管不良事件报告不理想,可能使安全性和疗效结果产生偏倚并降低试验外推性

研究设计与样本

  • 系统综述方法,检索MEDLINE、Embase和Cochrane Library数据库中2015至2025年发表的Ⅲ期多发性骨髓瘤药物随机对照试验
  • 纳入成人多发性骨髓瘤患者、每组≥100例的英文随机对照试验,排除非随机、亚组及仅摘要报告

主要发现

  • 淀粉样变性在30项试验中为排除标准,通常使用非特异性定义
  • 无任何试验报告对淀粉样变性进行主动筛查或评估心脏受累情况
  • 基线心血管检查常见但未用于识别心脏淀粉样变性
  • 98%的试验至少含一项心血管排除标准,最常见为心力衰竭和近期心肌梗死
  • 仅1项试验报告了基线心血管特征

关键数值与推荐

  • 纳入标准:2015至2025年发表的英文Ⅲ期随机对照试验,成人多发性骨髓瘤患者,每组≥100例
  • 排除标准:非随机试验、亚组报告、仅摘要报告
  • 30项试验将淀粉样变性列为排除标准,通常使用非特异性定义
  • 98%的试验至少含一项心血管排除标准,最常见为心力衰竭和近期心肌梗死

临床怎么用

  • 解读Ⅲ期多发性骨髓瘤试验心血管安全性信号时需考虑排除标准对人群选择的影响
  • 试验外推至合并心脏淀粉样变性或其他心血管疾病患者时应谨慎
  • 需改进试验中心血管事件的标准化定义与中心化裁定流程

局限性

  • 未对淀粉样变性进行主动筛查,无法明确心脏淀粉样变性真实患病率
  • 基线心血管特征报告严重不足,仅1项试验报告
  • 心血管不良事件为研究者报告,定义不一致且无中心裁定
  • 淀粉样变性排除标准多使用非特异性定义
  • 仅纳入英文发表试验,可能存在语言偏倚

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Cardiovascular disease (CVD) and light chain (AL) amyloidosis are important causes of morbidity and mortality in patients with multiple myeloma (MM). Additionally, MM therapies can have cardiovascular effects. However, the extent to which phase III MM trials account for underlying CVD and amyloidosis through eligibility criteria, screening and reporting remains uncertain. These elements of trial design and reporting are essential for accurate interpretation of cardiovascular safety signals. Objectives To examine practice-changing MM trials with respect to amyloidosis and CVD eligibility criteria, assessment for cardiac amyloidosis, reporting of baseline cardiovascular characteristics and cardiovascular adverse events (CVAE). Methods Systematic review of phase III randomised controlled trials of MM drug therapies published in English between 2015 and 2025, identified by searching MEDLINE, Embase and Cochrane Library. Eligible trials enrolled adults aged ≥18 years with MM and included ≥100 patients per treatment group; non-randomised, subgroup and abstract-only reports were excluded. Results 41 trials enrolling 20 144 participants were included. Amyloidosis was an exclusion criterion in 30 trials typically using non-specific definitions. No trial reported active screening for amyloidosis or assessment of cardiac involvement. Baseline cardiovascular investigations were common but were not used to identify cardiac amyloidosis. At least one cardiovascular exclusion criterion was present in 98% of trials, most commonly heart failure and recent myocardial infarction. Baseline cardiovascular characteristics were reported in only one trial. CVAEs were investigator-reported, inconsistently defined and not centrally adjudicated. Conclusions Phase III MM trials frequently incorporate amyloidosis and CVD exclusion criteria. However, the prevalence of cardiac amyloidosis and other CVD within these practice-changing MM trials remains poorly defined and CVAE reporting remains suboptimal. These limitations may bias safety and efficacy outcomes and reduce trial generalisability. PROSPERO registration number CRD420251125097.

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。